Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.
Treatment of advanced melanoma patients with ipilimumab results in improved survival. However, only about 20% of treated patients experience long-term benefit. Combining treatment of ipilimumab with other drugs may improve immune activation and potentially enhance clinical efficacy. The aims of the phase II clinical trial reported here were to investigate tolerability and efficacy of a combined immunotherapeutic strategy comprising standard systemic ipilimumab at 3 mg/kg four times at 3-week intervals and intratumorally injected IL-2 at 9 MIU daily twice weekly for four weeks in pretreated melanoma patients with distant metastasis. The primary endpoint was the disease control rate according to immune-related response criteria at week 12; tolerability according to Common Terminology Criteria for Adverse Events criteria was secondary endpoint. No objective responses were observed in the 15 enrolled patients. Three patients had stable disease 12 weeks after starting treatment, yielding a disease control rate of 20%. Tolerability of this combination treatment was acceptable. Observed adverse events were those expected from the respective monotherapies. Autoimmune colitis was observed in two patients. Grade III/IV adverse events were observed in 40% of patients, and no treatment-related deaths occurred. Thus, this combined immunotherapy is associated with adverse events similar to those associated with the respective monotherapies. However, this study does not provide any evidence of improved efficacy of the combination over ipilimumab alone.
['Weide|Benjamin|B|', 'Martens|Alexander|A|', 'Wistuba-Hamprecht|Kilian|K|', 'Zelba|Henning|H|', 'Maier|Ludwig|L|', 'Lipp|Hans-Peter|HP|', 'Klumpp|Bernhard D|BD|', 'Soffel|Daniel|D|', 'Eigentler|Thomas K|TK|', 'Garbe|Claus|C|']
D000911:Antibodies, Monoclonal D000971:Antineoplastic Combined Chemotherapy Protocols D003092:Colitis D005260:Female D006801:Humans D007167:Immunotherapy D007376:Interleukin-2 D000074324:Ipilimumab D008297:Male D008545:Melanoma D008875:Middle Aged D009362:Neoplasm Metastasis D009367:Neoplasm Staging D011446:Prospective Studies D012878:Skin Neoplasms D016896:Treatment Outcome
Ipilimumab Interleukin-2 Melanoma Clinical trial